Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;24(2):e86-e95.
doi: 10.1016/S1470-2045(22)00654-4.

Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group

Affiliations
Review

Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group

Claire Piccinin et al. Lancet Oncol. 2023 Feb.

Abstract

The use of item libraries for patient-reported outcome (PRO) measurement in oncology allows for the customisation of PRO assessment to measure key health-related quality of life concepts of relevance to the target population and intervention. However, no high-level recommendations exist to guide users on the design and implementation of these customised PRO measures (item lists) across different PRO measurement systems. To address this issue, a working group was set up, including international stakeholders (academic, independent, industry, health technology assessment, regulatory, and patient advocacy), with the goal of creating recommendations for the use of item libraries in oncology trials. A scoping review was carried out to identify relevant publications and highlight any gaps. Stakeholders commented on the available guidance for each research question, proposed recommendations on how to address gaps in the literature, and came to an agreement using discussion-based methods. Nine primary research questions were identified that formed the scope and structure of the recommendations on how to select items and implement item lists created from item libraries. These recommendations address methods to drive item selection, plan the structure and analysis of item lists, and facilitate their use in conjunction with other measures. The findings resulted in high-level, instrument-agnostic recommendations on the use of item-library-derived item lists in oncology trials.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests EB reports receiving personal consulting fees (as consultant or scientific adviser) from AstraZeneca, Carevive Systems, Navigating Cancer, Sivan Healthcare, and Resilience Health. MC has received funds for her institution (University of Birmingham, UK) from the National Institutes for Health Research (NIHR) Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Birmingham–Oxford Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics, NIHR Applied Research Collaboration West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, SPINE UK, UK Research and Innovation, UCB Pharma, Janssen, GSK, and Gilead; reports personal consulting fees from Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Gilead, Glaukos, GSK, and the Patient-Centered Outcomes Research Institute; has a family member who owns stock in GSK; and is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for Patient Reported Outcomes Research, and is an NIHR Senior Investigator. AC is employed by AstraZeneca and reports grants from Carevive, Takeda, Clinical Outcomes Solutions, and LUNGevity. DC reports receiving royalties or licences as President of FACIT.org and as President-Elect and Board Member of PROMIS Health Organization. CSC reports receiving licensing fees paid to both MD Anderson Cancer Center and to his limited liability company for the Brief Pain Inventory. BLK-K has received grants from AstraZeneca, G1 Therapeutics, Bristol-Myers Squibb, Merck, BluePrint Medicine, Eli Lilly, Genentech, Takeda, and Jazz Pharmaceuticals; consulting fees from Eli Lilly, Health Outcomes Solutions, University of South Florida, and Atheneum; and has participated on a data safety monitoring board or advisory board for Bristol-Myers Squibb. KO reports receiving honoraria (2010–20) from GSK for her involvement with the Healthcare Advisory Board and receiving an honorarium as a speaker at the Sharing Progress in Cancer Care webinar (October, 2021). All other authors declare no competing interests.

LinkOut - more resources